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Surgery, chemotherapy, and radiation therapy are standard modalities for cancer treatment,
but the effectiveness of these treatments has reached a plateau. Thus, other strategies
are being explored to combine with the current treatment paradigms in order to reach
better clinical results. One of these approaches is the active immunotherapy based on the
induction of anti-tumor responses by anti-idiotypic vaccination. This approach arose from
Jerne’s idiotypic network theory, which postulates that B lymphocytes forms a functional
network, with a role in the establishment of the immune repertoires, in the regulation of
natural antibody production and even in the establishment of natural tolerance. Due to the
large potential diversity of the immunoglobulin variable regions, the idiotypes repertoire
can mimic the universe of self and foreign epitopes, even those of non-protein nature,
like gangliosides. Gangliosides are sialic acid-containing glycolipids that have been consid-
ered attractive targets for cancer immunotherapy, based on the qualitative and quantitative
changes they suffer during malignant transformation and due to their importance for tumor
biology. Although any idiotype could be able to mimic any antigen, only those related to anti-
gens involved in functions relevant for organism homeostasis, and that in consequence has
been ﬁxed by evolution, would be able not only to mimic, but also to activate the idiotypic
cascades related with the nominal antigen.The present review updates the results, failures
and hopes, obtained with ganglioside mimicking anti-idiotypic antibodies and presents evi-
dences of the existence of a natural response against gangliosides, suggesting that these
glycolipids could be idiotypically relevant antigens.
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GANGLIOSIDES
Gangliosides are glycosphingolipids present in the outer leaﬂet
of the plasma membranes, where signiﬁcantly contribute to the
surface properties of cells (Sorice et al., 1997). These glycolipids
are involved in various cellular functions, including signal trans-
duction (Bremer et al., 1986; Fujitani et al., 2005), regulation of
cell proliferation and differentiation (Hakomori, 1970; Sakiyama
et al., 1972; Critchley and Macpherson, 1973; Yogeeswaran and
Hakomori, 1975), cell–cell recognition (Feizi, 1985), adhesion
(Cheresh et al., 1986), and cell death (De Maria et al., 1997, 1998;
Kirschnek et al., 2000; Colell et al., 2001). Gangliosides function
as the Ca2+ binding co-factor in synaptic transmission (Svenner-
holm, 1980), and as the co-factor of membrane adenylate cyclase
(Partington and Daly, 1979). Furthermore, they interact with, or
are the receptors of different bioactive molecules, such as bacterial
toxins (Simpson andRapport, 1971a,b;VanHeyningen et al., 1971;
Holmgren et al., 1973, 1980a; Kato and Naiki, 1976; Ledley et al.,
1977), glycoprotein hormones (Lee et al., 1976, 1977; Mullin et al.,
1976; Holmgren et al., 1980b), type 1 interferon (Besancon and
Ankel, 1974; Vengris et al., 1976; Ankel et al., 1980), ﬁbronectin
(Kleinman et al., 1979), lymphokines (Higgins et al., 1978;
Miura et al., 1979; Poste et al., 1979), and serotonin (Woolley and
Gommi, 1965).
The processes accompanying malignant transformation, like
oxidative stress, hypoxia, and angiogenesis, aswell as themetastasis
formation, induce the expression on cell membranes of potential
targets for cancer immunotherapy. It has been widely documented
that the expression patterns of membrane gangliosides suffer
quantitative and qualitative changes during neoplastic transfor-
mations (Brady et al., 1969; Hildebrand et al., 1972; Fishman,
1974; Keranen et al., 1976; Portoukalian et al., 1976). Normal
melanocytes express predominantly GM3, while GD3 increases
when these cells suffer an oncogenic process (Ravindranath et al.,
1991). GD3 plays a role in the regulation of cell growth and the
induction of angiogenesis by the tumor cells (Hedberg et al., 2000;
Zeng et al., 2000; Fredman et al., 2003). Melanoma GD3 carries
a ceramide portion with a long chain fatty acid, in contrast with
the GD3 expressed in the normal tissues that carries a shorter
chain fatty acid (Nudelman et al., 1982). Fucosyl GM1 is a unique
structure that is found in small cell lung cancers (SCLC) with a
very limited expression innormal tissues (Krug et al., 2004; Tokuda
et al., 2006). GD2 is highly expressed on neuro-ectodermal tumors
(Heimburg-Molinaro et al., 2011) and in sarcomas (Kailayangiri
et al., 2012). This ganglioside is also a cancer stem cells marker
and promotes tumorigenesis (Battula et al., 2012).
A very interesting case is the one of N-glycolylated (NeuGc)
gangliosides, since these glycolipids are not naturally expressed
in humans due to a genetic deletion in the gene that codes the
CMP-N-acetyl hydroxylase, enzyme that catalyzes the conversion
of N-acetyl to N-glycolyl sialic acid (Irie et al., 1998; Irie and
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Suzuki, 1998; Olson and Varki, 2003). However, both direct and
indirect studies have indicated that NeuGc is overexpressed in
several human tumors (Devine et al., 1991; Kawai et al., 1991;
Marquina et al., 1996; Malykh et al., 2001). The most accepted
theory for this phenomenon is the incorporation of NeuGc from
dietary sources. Free sialic acids from the medium can be taken up
into cells via pinocytosis. The content of the resulting pinocy-
totic vesicles and endosomes would eventually be delivered to
the lysosome, where a sialic acid transporter then delivers the
molecules into the cytosol (Bardor et al., 2005). Also endoge-
nous synthesis from glycolyl-CoA is a possibility (Malykh et al.,
2001). The explanation for the differential expression of these
antigens (Ag) in human normal and tumor tissues is that the
rapidly growing tumor tissues might be more efﬁcient at scaveng-
ing NeuGc. Furthermore, hypoxia induces the expression of sialin,
a sialic acid transporter on tumor cells, and enhances the incor-
poration of the non-human sialic acid from the external milieu
(Yin et al., 2006).
The gangliosides are not only attractive targets due to their
over-expression on tumor cells membranes but also because of
their importance for tumor biology. The metastatic capacity of the
cells is strongly affected by the gangliosides expressed on the cell
membranes: disialogangliosides GD2 and GD3 participate in the
anchoring of the melanoma and neuroblastoma metastatic cells
to the extracellular matrix proteins (Cheresh et al., 1986; Fred-
man et al., 2003). Comparing the ganglioside pattern expressed
by the primary tumor or the metastatic cells of a melanoma
patient, gangliosides expression was higher in the last ones, espe-
cially GD1. There were also abundant O-acetylation of GM2,
GD3, and GD2, which were absent in the primary tumor. GM2
is also strongly expressed in prostate metastasis (Zhang et al.,
1998), where is found in the areas of tumor cell-to-tumor cell
contact indicating a role in cellular interactions and adhesion
(Fredman et al., 2003).
Furthermore, gangliosides actively shed from tumors are
inserted into the plasmatic membrane of surrounding cells, affect-
ing the function of lymphocytes (Miller and Esselman, 1975;
Lengle et al., 1979; Whisler and Yates, 1980; Ladisch et al., 1983;
Gonwa et al., 1984), monocytes (Ladisch et al., 1984), natural
killer cells (Diatlovitskaia et al., 1985), and antigen-presenting
cells (Caldwell et al., 2003; Bennaceur et al., 2006). Gangliosides
have been found to shift the cytokine proﬁle from Th1 toward
the Th2 in affected cells (Crespo et al., 2006). Negative modula-
tion of CD4 molecule on T lymphocytes has been described for
both the N-acetylated (Sorice et al., 1995) and the N-glycolylated
variants (de Leon et al., 2006) of GM3 ganglioside. Ganglio-
sides have been reported to block the nuclear translocation of
NF-κB in human monocytes and dendritic cells (Caldwell et al.,
2003). GD3, isolated from the polar lipid fraction of ovarian
cancer-associated ascites, was shown to be an inhibitory factor
that prevents innate immune activation of natural killer T cells
(Webb et al., 2012). GM2 inhibits immunoglobulin production by
B cells (Kimata andYoshida, 1996). In this way tumor released gan-
gliosides reinforce tumor evasion by blocking the immunological
surveillance.
Despite the fact that gangliosides are poorly immunogenic,
due to their self and glycolipidic nature, several reports show
the presence of naturally occurring antibodies, not only in can-
cer patients, but also in healthy individuals, suggesting that
anti-ganglioside reactivity is ﬁxed in the natural antibodies
repertoire.
NATURALLY OCCURRING ANTI-GANGLIOSIDE ANTIBODIES
Natural antibodies are considered humoral mediators of innate
immunity and recognize antigens highly conserved throughout
evolution (Cojocaru et al., 2009). It has been proposed that natu-
ral auto-antibodies and auto-reactive T cells in healthy individuals
may be directed to a speciﬁc and limited set of self-molecules;
this selective autoimmunity has been termed the immunologi-
cal homunculus (Cohen, 2007). Due to the limited number of
mutations in the genes encoding the variable region of these
antibodies, the repertoire of these immunoglobulins is highly
conserved within species (Cojocaru et al., 2009). Several authors
have described their capacity to bind foreign antigens but also
self and altered self-antigens, which may be or not of protein
nature (Cohen, 2007). These antibodies recognize epitopes associ-
ated with pathogens, such as phosphorylcholine of Gram-positive
bacteria, lipopolysaccharide (LPS) of Gram-negative bacteria, and
various molecules expressed by parasites (Ochsenbein et al., 1999;
Baumgarth et al., 2005). For this reason they are considered as a
ﬁrst, quick anti-infection barrier that helps to guarantee the sur-
vival since the very beginning of the organisms’ life. Among their
targets have also been identiﬁed intracellular molecules, such as
somenuclear (e.g., histones) and cytoskeleton (e.g., actin) proteins
(Coutinho et al., 1995) and single-strandedDNA(Schwartz-Albiez
et al., 2009). They also recognize peptides (e.g., amyloid beta
peptide), plasma membrane glycoproteins (e.g., CD90; Schwartz-
Albiez et al., 2009), oxidized lipids (e.g., phosphatidylcholine), and
antigens expressed by apoptotic cells (Annexin IV; Chou et al.,
2009; Baumgarth, 2011). Mounting evidence suggest that natu-
ral IgM antibodies, through this self-reactivity might contribute
to critical innate immune functions involved in the maintenance
of tissue homeostasis, like the clearance of apoptotic cells (Chou
et al., 2009), reduction of atherosclerotic lesions (Hartvigsen et al.,
2009; Cesena et al., 2012), and the reinforcement of mechanisms
involved in the protection from the development of autoimmune
disease (Werwitzke et al., 2005; Chen et al., 2009a,b; Silverman
et al., 2009; Jiang et al., 2011; Stoehr et al., 2011).
Recently it has been described the existence of auto-antibodies
against tumor-associated antigens, which can arise in the patients
evenbefore the symptomsbecome evident and that canbedetected
also in healthy donors (Zhang et al., 2003; Storr et al., 2006;
Chapman et al., 2008). Some of these IgM isotype, germline anti-
bodies have been isolated from cancer patients and have proved
to be able not only to recognize tumor cells, but also to kill
them by different mechanisms (Bohn, 1999; Hensel et al., 2001;
Jakobisiak et al., 2003; Vollmers and Brandlein, 2005, 2006; Lutz
et al., 2009). Many of the detected anti-tumor antibodies bind
to carbohydrate repeated motifs, including sequences of sugars
contained in gangliosides (Lutz and Miescher, 2008; Cojocaru
et al., 2009).
Naturally occurring antibodies reacting with tumor-associated
gangliosides have been detected in cancer patients but also in
healthy donors. Antibodies against GM2 and GD2 were detected
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in the sera of both melanoma patients and healthy individu-
als (Watanabe et al., 1982; Tai et al., 1985). Other authors have
reported the existence in healthy donors of naturally occurring
antibodies with reactivity against gangliosides like GM1, GD1a,
GD1b, and GT1b (Mizutamari et al., 1994; Ravindranath et al.,
1997; Lardone et al., 2006). Silent auto-reactive B clones have
also been identiﬁed in cancer patients, from which human mon-
oclonal antibodies (mAb) against gangliosides were generated.
The mAb GMA1 reacted with the gangliosides GD3, GM3, and
GD2 from melanoma and neuroblastoma cell lines and not nor-
mal tissues (Mukerjee et al., 1998). The human monoclonal IgM
antibody 7c11.e8, also generated by fusing lymph node cells iso-
lated from a surgical specimen of malignant melanoma reacted
with GM4, GM3, and GD3. In the presence of human serum
the antibody initiated a strong lysis of melanoma tumor cells
in complement-dependent cellular cytotoxicity (CDCC) assays
(Abdel-Wahab et al., 1993).
The presence of naturally occurring antibodies that recognize
NeuGc acid present in tumor-associated glycoconjugates has also
been described. It has been shown that normal human serum
contains high levels of NeuGc-speciﬁc antibodies, which attract
complement molecules to the surface of leukemic cells expressing
NeuGc, but not other normal cells (Zhu and Hurst, 2002; Tangvo-
ranuntakul et al., 2003; Nguyen et al., 2005; Padler-Karavani et al.,
2008). Ravindranath et al. (2007), examining the sera of healthy
volunteers between the ages of 18 and 90, reported that anti-
ganglioside antibodies occurred naturally and that their levels
decline after 50 years, which could be relevant since the cancer
incidence increases with age.
Anti-ganglioside antibodies have shown to have anti-tumor
cytotoxic capacities. It has been reported the ability of a murine
anti-GM2 to induce apoptosis through caspase activation in lym-
phoma, melanoma, and lung cancer cells expressing the antigen
(Retter et al., 2005). The binding of an anti-GD2 antibody to the
ganglioside expressed in lung cancer cells induced apoptosis by the
reduction in the levels of phosphorylation of FAK and activation
of mitogen-activated kinase p38. Immunoprecipitation experi-
ments showed a physical association of GD2 with integrins, which
were associated with FAK inside the membrane. Antibody bind-
ing to ganglioside caused conformational changes in this complex,
inducing the transmissionof intracellular signals thatmediated the
apoptosis (Aixinjueluo et al., 2005). It has been also proved that
anti-GD2 antibodies of healthy donors have cytotoxic capacity
against neuroblastoma cells (Ollert et al., 1997).
The capacity of the mAb 14F7, a murine IgG highly speciﬁc for
NeuGcGM3, to induce oncotic cell death to tumor cells expressing
this antigen has been reported. This antibody induced a tumor cell
death that was accompanied by cellular swelling,membrane lesion
formation, and cytoskeleton activation (Carr et al., 2000; Roque-
Navarro et al., 2008). Another antibody speciﬁc for N-glycolylated
gangliosides is P3 mAb. This is an IgM, germline encoded that
is able to induce complement-mediated cytotoxicity to NeuGc
expressing tumor cells (Vázquez et al., 1995; Carr et al., 2002). It
has been reported that naturally occurring anti-NeuGc in healthy
humans were able to kill human leukemic cells that were exoge-
nously fed with NeuGc by a complement-mediated mechanism
(Nguyen et al., 2005).
These evidences suggest that the evolution has ﬁxed an innate
immunity against gangliosides in the natural antibodies repertoire,
which could play an important role for tumor immune surveil-
lance. Since the natural antibodies secreting B cells arise in the
neonatal period, they could be connected and regulated by anti-Id
interactions, according to Jerne’s idiotypic network theory.
THE IDIOTYPIC NETWORK THEORY
In 1974,Neils Jerne published the IdiotypicNetwork theory,which
gave a different view of the immune system organization and
the recognition of the “self.” According to classical clonal selec-
tion theory, the immune system was “antigen driven” and in the
absence of an external antigen challenge the system should be pas-
sively inactive. In contrast, according to the network theory, the
immune system consists of lymphocyte clones which are stimu-
lated and regulated by the immunoglobulins produced by other
clones within the network. Since a huge diversity of idiotypes
(Id) is generated by random somatic rearrangements of genes,
idiotype’s complementary structures can be found not only on
antigens but also on antibodies of different idiotypes. In Jerne’s
ownwords“the immune systemof a single animal, after producing
speciﬁc antibodies to an antigen, continues to produce antibodies
to the idiotopes of the antibodies which it has itself made. The lat-
ter anti-Id antibodies likewise display new idiotypic proﬁles, and
the immune system turns out to represent a network of idiotypic
interactions” (Jerne, 1974, 1985).
This phenomena was extensively proved ﬁrstly by Kunkel and
Oudin, who showed that ordinary antibody molecules that arise
in an immunized animal are antigenic and induce the formation
of speciﬁc anti-antibodies (Kunkel et al., 1963; Oudin and Michel,
1963). Later experiments further demonstrated that the recog-
nition of self-idiotopes by B or T cells is an active physiological
process controlling the suppression or expansion of the immune
response (Eichmann and Rajewsky, 1975; Cazenave, 1977; Urbain
et al., 1977; Bona et al., 1981).
This immune network is established in the neonatal period,
thus this theory predicts that the immune systems has an
autonomous activity, manifested by the presence of activated lym-
phocytes and antibody secretion, before any external immuniza-
tion. This prediction was conﬁrmed by studies on “antigen-free”
animals, which contain in their spleen and peritoneal cavity acti-
vated B cells that secret IgM antibodies and T lymphocytes that
perform as effector cells, help or suppress the antibody production
(Hooijkaas et al., 1984; Pereira et al., 1986).
Thus, a network of idiotypically interacting immune cells is
formed, that has a dynamic equilibrium between the idiotypes,
anti-Id, and the normal self-constituents of our body, inﬂuencing
the shaping of the B- and T cell repertoires, and controlling auto-
reactive clones.
In the 1980s, there was an interesting debate between the pro-
ponents of the network paradigm and those of the clonal selection
theory and several experiments were performed that provided evi-
dences about both ideas (Cohn, 1981, 1986; Langman and Cohn,
1986; Cazenave, 1988; Behn, 2007).
The establishment of collections of antibody-producing
hybridomas, derived fromnormal, unimmunizedmice at different
stages of ontogeny, provided proof for the existence of idiotypic
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connectivity (Holmberg et al., 1984a). Matrices of idiotypic com-
plementaritieswere established, that allowed to estimate the degree
of connectivity within different B cell populations (Holmberg
et al., 1984a,b, 1986a,b,c; Kearney and Vakil, 1986). High levels of
connectivity were observed within collections of fetal or neonatal
origin (Holmberg et al., 1984b). However, within collections from
the adult lymphocyte population the degree of connectivity was
10- to 100-fold lower (Holmberg et al., 1986c). These experiments
suggested that high idiotypic connectivity is not an intrinsic prop-
erty of any collection of IgM antibodies, but a distinctive property
of part of the perinatal antibody repertoire.
Then, Varela and Coutinho formulated the concept of second-
generation immune networks (Coutinho, 1989; Varela and
Coutinho, 1991), which tried to combine the two competing
paradigms. They adopted the view that the immune system is
formed by two compartments of B and T lymphocytes: a majority
of small resting cells constituting 80–85% of the total population
and a set of large activated cells making up the other 15–20%
(Pereira et al., 1985, 1986), this last being the predominant in the
neonatal period. The speciﬁc response to a foreign antigen would
be mainly caused by the activation of resting lymphocyte clones,
which are only poorly connected to the network, thus forming the
peripheral part of the system. The fraction of highly connected
cells forms the actual network, a compartment of naturally acti-
vated lymphocytes. The immune network includes, in addition
to V-regions, all other molecules of the somatic self. This pool
of connected cells may be responsible for maintenance of normal
network dynamics and prevention of auto-aggression.
The idiotypic network hypothesis predicts that due to the
huge diversity of immunoglobulin variable regions, and since
each antibody will bind its nominal antigen and also other
immunoglobulins, within the immune network the universe of
external antigens is mimicked by idiotypes. According to this
concept, immunization with a given antigen will generate the pro-
duction of antibodies against this antigen termed Ab1. This Ab1
can generate a series of anti-Id antibodies against Ab1 termedAb2.
The particular anti-Idswhich ﬁt into the antigen binding site of the
Ab1, can induce a speciﬁc immune responses against the nominal
antigen. Then, a practical consequence of the idiotypic network
theory was that the idiotopes could be used to mimic any exist-
ing antigen and used as surrogate antigens. Immunization with
Ab2 can lead to the generation of anti-anti-Id antibodies (Ab3)
that recognize the corresponding original antigen identiﬁed by
the Ab1 (Figure 1). Several such Ab2 have been used to trigger
the immune system to induce speciﬁc and protective immunity
against tumor antigens (Miller et al., 1982; Jerne, 1985; Lee et al.,
1985; Raychaudhuri et al., 1986).
Although Jerne, in his original network hypothesis, and later
Coutinho with the second generation networks outlined the
importance of naturally occurring idiotypic complementaries,
must of the studies using anti-Id as vaccines are focus on the great
mimetic capacity of idiotypes, no in activating network related
properties, like immune regulation and natural immune surveil-
lance. Beyond the functional mimetic capacity, those anti-Id
antibodies related with antigens connected and regulated though
networks due to their importance for organisms’ homeostasis,
could be able to activate natural antibodies secreting B cells. Their
antigens, especially self-antigens, could be the suited ones to get
targeted through the idiotypic vaccination. This could be the case
of gangliosides.
ANTI-GANGLIOSIDE IDIOTYPIC VACCINES
Anti-idiotype antibodies that mimic ganglioside have been uti-
lized as active speciﬁc immunotherapy in patients with different
tumors. Chapman and Houghton (1991) generated in syngeneic
mice the anti-Id antibody BEC2 against the anti-GD3 mAb R24.
In studies in rabbits this antibody demonstrated its ability to
mimic GD3, inducing a speciﬁc antibody response of IgG and
IgM isotypes. In clinical trials in melanoma patients treated by
surgery and with high risk of recurrence (McCaffery et al., 1996)
and in patients with SCLC with limited disease (Grant et al.,
1999) BEC2 demonstrated to be immunogenic and to induce
anti-anti-Id response when administered with the adjuvant BCG.
However, it induced speciﬁc anti-GD3 antibodies only in a low
percentage of patients (Chapman and Houghton, 1991; McCaf-
fery et al., 1996; Grant et al., 1999). The conjugation of BEC 2
to KLH did not increase but reduced the magnitude and fre-
quency of the anti-GD3 response. When anti-GD3 antibodies
were induced, they were detected only by ELISA, not by TLC
immunostaining (Ritter et al., 1991) or by ﬂow cytometry against
GD3-positive melanoma cell lines, suggesting that these anti-GD3
antibodies had a relatively low avidity for cell surface GD3. A
phase III trial with 515 patients with limited-disease SCLC after
a major response to chemotherapy and chest radiation was per-
formed with BEC2/BCG. This trial failed to show any survival
advantage for vaccinated patients. Only one-third of the patients
elicited an anti-GD3 response. Among vaccinated patients, a trend
toward prolonged survival was observed in those who developed
the humoral response (P = 0.085), so that it was suggested that
the induction of higher titers of antibodies in a larger proportion
of patients could make an impact on median survival (Giaccone
et al., 2005).
Another trial that targeted a ganglioside, utilized a vaccine com-
posed of an anti-Id mimicking GD2 injected with the adjuvant
QS21, a preparation called TriGem. The anti-Id mAb, called 1A7
is a functional mimic of a speciﬁc epitope in the ganglioside GD2.
In preclinical studies inmice, rabbits, andmonkeys the immuniza-
tion with 1A7 antibody induced a speciﬁc IgG response against the
ganglioside, capable of causing the lysis of GD2-positive cells on
ADCC assays (Sen et al., 1998).
Foon et al. (1998) initiated a clinical trial in patients with
advanced melanoma, which were given anti-Id mAb 1A7 with the
adjuvant QS21. All sera showed an anti-anti-Id response mainly
of the IgG1 isotype. The puriﬁed Ab3 from all patients inhib-
ited the binding of the Ab1 to a GD2-positive cell line and to
puriﬁed GD2. In addition, sera speciﬁcally reacted with tumor
cells expressing GD2 and were positive in ADCC studies. One
patient had a complete clinical response and 6 patients, of a total
of 12 enrolled in the trial were stable from 9 to 23 months. In
a similar trial, 47 patients with advanced melanoma received 1,
2, 4, or 8 mg doses of TriGem. Hyperimmune sera from 40 of
the 47 patients showed an anti-anti-Id response of IgG isotype
that speciﬁcally bound puriﬁed GD2. One patient had a complete
response that persisted at 24 months, and 12 patients were stable
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FIGURE 1 | According to the idiotypic network theory, idiotype’s
complementary structures can be found not only on antigens but
also on antibodies of different idiotypes.The immune system after
producing speciﬁc antibodies to an antigen (Ab1), continues to produce
antibodies to the Ab1 idiotopes (Ab2). The particular Ab2 which ﬁt into
the antigen binding site of the Ab1, can induce a speciﬁc immune
responses against the nominal antigen. Thus, the idiotopes could be
used as surrogates of any existing antigen. Immunization with Ab2 can
lead to the generation of anti-anti-Id antibodies (Ab3) that recognize the
corresponding original antigen identiﬁed by the Ab1. Several Ab2 have
been used to induce speciﬁc and protective immunity against tumor
antigens.
from 14 to 37 months (median, 18 months). These results showed
that this vaccine had minimal toxicity, induced a strong response
against GD2 and seemed to have a favorable impact on the reduc-
tion of disease progression and survival of patients (Foon et al.,
1998, 2000).
In 2003, Basak and colleagues generated Ab2 against the anti-
GD2 mAb ME361. These Ab2s induced a speciﬁc DTH response
in mice against melanoma cell lines that express this ganglioside.
Furthermore, these antibodies were able to induce proliferative
responses in cells from a melanoma patient confronted with
human melanoma cells expressing GD2 in vitro, demonstrating
the ability of these antibodies to induce cellular responses against
carbohydrate antigens (Basak et al., 2003).
Several evidences have shown that tumor antigen-speciﬁc
antibodies Ab1, used in preclinical experiments or for diagnos-
tic and/or therapeutic purposes, may contribute to anti-tumor
effects by triggering the idiotypic cascade and inducing a tumor
antigen-speciﬁc immune response. The triggering of the idiotypic
cascade has been reported to be associated with a favorable clinical
response to antibody-based therapy in patients with neuroblas-
toma, colorectal carcinoma, ovarian carcinoma, andnon-Hodgkin
lymphoma (Koprowski et al., 1984; Saleh et al., 1993; Cheung et al.,
1994, 2000; Schultes et al., 1998). GD2 ganglioside-speciﬁc anti-
bodies have been induced in patients with neuroblastoma treated
with anti-GD2 ganglioside antibodies.
Treatment with the anti-GD2 monoclonal antibody 3F8 (Ab1)
at the time of remission prolonged the survival of children with
stage 4 neuroblastoma. Among 34 patients treated with this anti-
body at the end of chemotherapy 14 were alive, and 13 (1.8–7.4
years at diagnosis)were progression-free (53–143months from the
initiationof 3F8 treatment)without further systemic therapy at the
moment of the report. This long-term progression-free survival
and survival correlated signiﬁcantly with the induction of Ab3
anti-GD2 response (Cheung et al., 2000). These results reinforce
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the importance of GD2 as a tumor target, and the connectivity
capacity of anti-ganglioside antibodies.
Our group has developed a vaccine preparation featuring a
murine anti-Id mAb related to the NeuGc-containing ganglio-
side antigen model. This Ab2, named 1E10 (Vázquez et al., 1998),
was generated from the immunization of BALB/c mice with P3,
an idiotypic antibody (Ab1) that recognizes NeuGc-containing
gangliosides, sulfated glycolipids, and antigens present in differ-
ent human tumors including those from the lung. This Ab1 is
highly immunogenic in the syngeneic model, inducing an anti-Id
response in the absence of adjuvant or carrier protein. Further-
more, theAb1 P3was able to activate NeuGcGM3 related idiotypic
cascade, since antibodies against NeuGcGM3 (Ab3, Ab1 like) were
detected in chickens immunized with this Ab1. The detection of
Abs with this speciﬁcity in animals immunized with an Ab1 sug-
gested that the elicited Ab2s behaved as a ganglioside surrogate
inducing a speciﬁc Ab3 response against this antigen.
Preclinical data published by our group suggest that P3 and
1E10 mAb could be able to activate idiotypic networks, involving
both B and T cells. Lymph node cells from BALB/c mice immu-
nized with P3 mAb proliferated in vitro, in a dose-dependent
manner, not only in response to P3 mAb but also to 1E10
mAb, suggesting the existence of a naturally occurring B/T
cell idiotypic network (Perez et al., 2002). Phase I clinical trials
have proven the safety and immunogenicity of 1E10 Id vacci-
nation in melanoma, breast, and lung cancer patients (Alfonso
et al., 2002, 2007; Diaz et al., 2003; Neninger et al., 2007; Her-
nandez et al., 2008). In all the cases, 1E10 idiotype proved to
be immunodominant, since the induced anti-anti-Id response
was signiﬁcantly higher than the anti-isotypic response. Similar
results were obtained when monkeys and chickens were immu-
nized with 1E10 mAb (Hernandez et al., 2005), suggesting that
1E10 mAb Id immunodominance is not a species-depending
property. High titer antibody responses to NeuGc-containing
gangliosides were measured in the sera of cancer patients and
were conﬁrmed by TLC immunostaining. Interestingly, a fraction
of non-suppressible anti-NeuGc-containing ganglioside Abs was
demonstrated after the adsorption of the patients’ sera with 1E10
mAb, suggesting that 1E10 Id vaccination was activating natural
anti-NeuGcGM3 responses (Hernandez et al., 2008). The antibod-
ies that recognize both 1E10 and the ganglioside (Id+Ag+) and
the ones that recognize the ganglioside but not the immunizing
Ab3 (Id−Ag+), recognized and induced the death of tumor cells
expressing NeuGcGM3 by an oncotic necrosis mechanism. Those
patients who developed IgG and/or IgM Abs against NeuGcGM3
showed a longer survival time. We hypothesize that 1E10 Id
vaccination could be activating an existing idiotypic cascade
related with N-glycolylated gangliosides, which would amplify
FIGURE 2 |Timeline of highlight milestones in the development of anti-idiotypic vaccination against tumor gangliosides.
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the antigen-speciﬁc immune response to a tumor-associated neo-
self antigens. This therapeutic concept goes beyond the classical
concept of antigen mimicry. A randomized, double blind phase
II clinical trial is ongoing to evaluate the clinical effect of 1E10
mAb vaccine in NSCLC patients and to deﬁne the value of the
Abs induced by the anti-Id treatment as real predictors of clini-
cal outcome. For a chronological representation of the principal
milestones in the development of anti-Id vaccines against tumor
expressed gangliosides see Figure 2.
CONCLUDING REMARKS
At present, most of the anti-Id vaccine approaches are based
and study the mimetic capacity of the anti-Id antibodies, with-
out searching for their immunoregulatory or natural anti-tumor
potential. The use of anti-Id antibodies as immunogens could
offer the possibility not only to generate Ab3 antibodies against
their own idiotopes, but also to inducing a cascade of Id–anti-
Id interactions leading to an ampliﬁed and long lasting immune
response against the nominal antigen. This immunization could
also involve T cells in the response against glycolipidic antigens.
The expansion of natural antibodies repertoire by idiotypic vac-
cination could even participate in the lysis of tumor cells by the
activation of evolutionarily ﬁxed anti-tumor mechanisms. A nat-
urally occurring antibody response against ganglioside, which has
shown to carry anti-tumor properties, exists in healthy individuals
and cancer patients. The idiotypic vaccination could be an opti-
mum way to activate the idiotypic B and T cell cascades involving
the natural responses against these antigens.
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